Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Pharmacotherapy in Treatment of Meningioma: A Systematic Review Publisher



Shahbandi A1 ; Shah DS2 ; Hadley CC3 ; Patel AJ3, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurological Surgery, School of Medicine, Tehran University of Medical Sciences, Tehran, 1416634793, Iran
  2. 2. Department of Neurological Surgery, Dell Medical School, Austin, 78712, TX, United States
  3. 3. Department of Neurosurgery, Baylor College of Medicine, Houston, 77030, TX, United States
  4. 4. Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, 77030, TX, United States
  5. 5. Jan and Dan Duncan Neurological Research Institute, Texas Children’s Hospital, Houston, 77030, TX, United States

Source: Cancers Published:2023


Abstract

The safety and efficacy of various pharmacotherapeutic regimens on refractory meningiomas have been the focus of investigations. We present a comprehensive review of the previous efforts and the current state of ongoing clinical trials. A PRISMA-compliant review of the MEDLINE and ClinicalTrial.gov databases of the National Library of Medicine were performed. The primary outcomes of interest for included articles were radiographic response, overall survival, progression-free survival, six-month progression-free survival, and adverse events. Overall, 34 completed trials and 27 ongoing clinical trials were eligible. Six-month progression-free survival was reported in 6–100% of patients in the completed studies. Hematological disorders were the most common adverse events. Of the ongoing clinical trials identified, nine studies are phase I clinical trials, eleven are phase II trials, two are phase I and II trials, one is phase II and III, and two trials do not have a designated phase. Currently, there is no effective chemotherapy for refractory or recurrent meningiomas. Several promising targeted agents have been developed and are currently being investigated in the hope of identifying novel therapeutic strategies for the treatment of this pathology. © 2023 by the authors.
Related Docs
1. A Novel Nbn Germline Mutation As the Likely Inherited Etiology of Various Cancer Types in an Iranian Family, Egyptian Journal of Medical Human Genetics (2025)
2. Application of Bevacizumab in the Management of Meningiomas: A Systematic Review and Meta-Analysis, Neurosurgical Review (2024)